CAZZANIGA MARINA ELENA

Turner, N., Saura, C., Aftimos, P., Van Den Tweel, E., Oesterholt, M., Koper, N., et al. (2025). Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). JOURNAL OF CLINICAL ONCOLOGY, 43(5), 513-523 [10.1200/JCO.24.00529]. Dettaglio

Cazzaniga, M., Huober, J., Tamma, A., Emde, A., Thoele, K., O'Shaughnessy, J. (2025). Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer. CLINICAL BREAST CANCER, 25(4), 307-324 [10.1016/j.clbc.2024.12.011]. Dettaglio

Cazzaniga, M., Pepe, F., Rossi, E., Coltelli, L., Beano, A., Valerio, M., et al. (2025). A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial. CLINICAL BREAST CANCER, 25(6), 560-565 [10.1016/j.clbc.2025.05.003]. Dettaglio

Ardakani, K., Pepe, F., Capici, S., Clementi, T., Cazzaniga, M. (2025). Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). CURRENT ONCOLOGY, 32(7) [10.3390/curroncol32070387]. Dettaglio

Cazzaniga, M., Pronzato, P., Amoroso, D., Arpino, G., Atzori, F., Beano, A., et al. (2025). Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study. CANCERS, 17(10) [10.3390/cancers17101715]. Dettaglio